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Abstract 
(Purpose) To investigate the incorporation of functional lung image-derived low 
attenuation area (LAA) based on four-dimensional computed tomography (4D-CT) 
into respiratory-gated intensity-modulated radiation therapy (IMRT) or volumetric 
modulated arc therapy (VMAT) in treatment planning for lung cancer patients with 
chronic obstructive pulmonary disease (COPD). 
(Materials and Methods) Eight lung cancer patients with COPD were the subjects  
of this study. LAA was generated from 4D-CT data sets according to CT values  
lower than -860 Hounsfield units (HU) as a threshold. The functional lung image  
was defined as the area where LAA was excluded from the image of the total lung.  
Two respiratory-gated radiotherapy plans (70 Gy/35 fr) were designed and  
compared in each patient as follows: 1) Plan A: anatomical IMRT or VMAT  
plan based on the total lung 2) Plan F: functional IMRT or VMAT plan based on  
the functional lung. Dosimetric parameters (V20: the percentage of total lung  
volume irradiated with ≥ 20 Gy, MLD: mean dose of total lung) of the two  
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plans were compared.  
(Results) V20 was lower in Plan F than in Plan A (mean 1.5 %, p= 0.025 in IMRT, 
mean 1.6 %, p= 0.044 in VMAT) achieved by a reduction in MLD (mean 0.23 Gy, 
p= 0.083 in IMRT, mean 0.5 Gy, p= 0.042 in VMAT). No differences were noted in 
target volume coverage and organ-at-risk doses.  
(Conclusions) Functional image-guided radiotherapy planning based on LAA in  
respiratory-guided IMRT or VMAT appears to be effective in preserving a  
functional lung in lung cancer patients with COPD.  
 
【Key Words】 functional imaging, 4D-CT, IMRT, COPD 
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INTRODUCTION 
One of the most severe complications in radiation therapy for lung cancer is 
radiation pneumonitis (RP). Reduction of the incidence of severe RP requires a 
reduction of the lung dose, such as V20 which is defined as the percentage of 
pulmonary volume irradiated to ≥ 20 Gy. It is also one of the significant dosimetric 
risk factors for the incidence and severity of RP (1). Chronic obstructive pulmonary 
disease (COPD) is a recognized risk factor for RP (2). There has been a worldwide 
increase of the prevalence of COPD and as the population ages, the incidence of 
COPD is expected to increase (3). Pulmonary emphysema (PE) is a subtype of 
COPD, and defined pathologically as a group of diseases that demonstrate 
anatomic alterations in the lung, characterized by enlargement of airspaces distal to 
the terminal bronchioles, accompanied by destructive changes of alveolar walls (4). 
These lesions are seen as low-attenuation areas (LAAs) on CT scans, and are 
established findings on the imaging diagnosis of COPD (5, 6). Kimura et al 
reported a correlation between the incidence of RP and the extent of LAAs in the 
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whole lung fields (7). From these results, the functional lung image-derived LAA 
based on four-dimensional computed tomography (4D-CT) was developed for 
planning of radiation treatment to reduce the risk of RP in patients with COPD.   
Several authors have described functional imaging modalities for planning of 
radiation treatment, such as ventilation imaging with 4D-CT (8) and single-photon 
emission computed tomography (SPECT) lung perfusion imaging (9). All of these 
authors showed that functional lung regions could be identified with imaging and then 
avoided with IMRT treatment planning techniques. Matsuoka (6) suggested that paired 
inspiratory and expiratory CT imaging can be used to define LAA volumes in patients 
with COPD. Therefore, these two approaches were combined in order to address the 
respiratory problem. This study investigated the ability of functional lung 
image-derived LAA based on 4D-CT, and its incorporation into respiratory-gated 
intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy 
(VMAT) in treatment planning for lung cancer patients with COPD.  
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Materials and Methods 
Patient background 
In this study, eight male patients with lung cancer were enrolled who had  
undergone 4D-CT scanning and definitive radiation therapy at Hiroshima 
University from 2009 to 2010. Pathological diagnosis, stage (UICC 7th edition), 
and the primary tumor location are summarized in Table 1. All patients received 
[18F] fluorodeoxyglucose-positron emission tomography (FDG- PET) for staging. 
Functional lung image-derived LAA based on 4D-CT 
At first, 4D-CT scans were acquired with 2.5-mm-thick slices using multi 
detector-row CT (MDCT; LightSpeed, GE Medical systems, Waukesha, WI) in 
cine mode with the Varian Real-time Position Management (RPM) Respiratory 
Gating system (Varian Medical Systems, Palo Alto, CA). Following image 
acquisition, the CT image data set was sorted into 10-phase bins of the respiratory 
cycle, and phase by phase evaluation was performed on a workstation 
(AdvantageSim, GE Healthcare, Princeton, NJ). The 10-phase set consisted of 0 to 
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90% in steps of 10 %, and 0 or 90 % was in the end-inspiratory phase and 50% in 
the end-expiratory phase. All 10-phase CT data sets were imported into the Eclipse 
treatment planning system (Varian Medical Systems, Palo Alto, CA). Several 
authors reported that the threshold CT value for the detection and quantification of 
LAA ranged from -850 to -950 HU (10, 11). Matsuoka et al concluded that the 
threshold of -860 HU correlated closely with airway dysfunction in COPD on 
paired inspiratory and expiratory CT (6). Therefore LAAs were generated from 
10-phase 4D-CT data sets according to CT values lower than -860 Hounsfield units 
(HU) as a threshold on Eclipse.  
For respiratory gated planning in this study, three expiratory phases (40-60%) 
were selected with the phase gating method. Fig 1 shows the three steps involved in 
making the functional lung image-derived LAA based on 4D-CT of case 1.  
1) Acquisition of LAA at each phase (the threshold of -860HU). 
2) Fusion of LAA at three expiratory phases (40-60%), and trimming the ROI as 
LAA image (40-60%). 
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3) The functional lung image was defined as the area where LAA image (40-60%) 
was excluded from fusion images of the total lung volumes on each of the 40-60% 
phases.  
 This technique did not employ any sort of deformable image registration algorithm in 
any of the steps.   
Respiratory Gated IMRT and VMAT planning with functional lung image 
In this simulation study, two respiratory-gated radiotherapy plans were designed 
and compared for each patient as follows: 1) Plan A: anatomical IMRT or VMAT 
plan based on the total lung; 2) Plan F: functional IMRT or VMAT plan based on 
the functional lung. RapidArc (Varian Medical Systems, Palo Alto, CA) was used 
as VMAT. In this study, IMRT was defined as fixed, non-rotational IMRT, and 
VMAT was defined as rotational IMRT. All dose calculations were done on the full 
expiration (50%) phase. 
For target delineation of each plan, a physician delineated the target volume on 
each 10-phase CT image. Gross tumor volume (GTV) included the primary tumor 
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and metastatic lymph nodes, and clinical target volume (CTV) margin of 3-5 mm 
was added to GTV according to the pathology. Elective nodal irradiation was 
omitted (so-called “involved-field”). Internal target volume (ITV) was defined as 
the sum of CTV at three expiratory phases (40-60%) in this respiratory gated 
planning. A planning target volume (PTV) margin of 5-10 mm was added allowing 
for reproducibility of respiratory motion and setup error to ITV.  
The IMRT plans consisted of five coplanar fixed beams with gantry angles of 
20°, 320°, 240°, 180°, and 135° at the right lung, and 340°, 40°, 120°, 180°, and 
215° at the left lung. The VMAT plans consisted of two coplanar arcs with gantry 
angles were moved 220° from 180° to 40° in the right lung, and from 180° to 320° 
in the left lung in clockwise and counter clockwise directions. Treatment plans 
were delivered using 6-MV photons generated by a linear accelerator (Clinac iX, 
Varian Medical Systems, Palo Alto, CA) with continuous changes in the gantry 
speed, multi-leaf collimator position, and dose rate. The collimator angle was fixed 
at 45° throughout the arc. The same beam arrangements were used for both plans.  
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A total dose of 70 Gy in 35 fractions to 95% of the PTV was prescribed. The prescribed 
dose was calculated with a heterogeneous dose calculation algorithm (the Eclipse 
anisotropic analytical algorithm; AAA). Table 2 shows the dose constraints for 
each structure. The constraints on the total lung were used in Plan A, and those on 
the two functional lung regions were used in Plan F. V20 or functional V20 (fV20) 
was calculated by lung-PTV and its dose constraints were defined as less than 
10-30%. Therefore the background of patients included all stages. The minimal 
value of V20 which could be achieved in the anatomical plan of each patient was 
selected according to the field size of each patient, and the value of fV20 was also 
the same. Several IMRT and VMAT plans were made to maintain clinical 
acceptability, and the plans which most suitably satisfied the dose constraints in 
Table 2 were selected for Plans A and F.  
Data analysis and Statistical methods 
The dosimetric parameters of Plans A and F using respiratory guided IMRT and 
VMAT planning were evaluated by examining the following: 
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1) Lung V5-30 and fV5-30: the percentage of total or functional lung volumes 
irradiated with ≥5-30 Gy 
2) Lung MLD and functional MLD (fMLD): mean dose to total or functional lung  
3) Mean dose, homogeneity index (HI), and conformity index (CI) of PTV 
HI = maximum dose of PTV / minimum dose to PTV 
CI = Treated Volume / PTV; it is implied that Treated Volume completely 
encompasses the PTV 
4) Mean or maximum dose of organ-at-risk (heart, esophagus, and spinal cord) 
5) Monitor units of each plan 
For comparison of statistical significance the Mantel-Haenzel χ2 or t tests were 
used. All statistical analysis was performed using StatMate for Windows (StatMate 
ver 4.01; ATMS, Tokyo, Japan). Statistical significance was defined as p<0.05. 
 
Results 
Details of target characteristics 
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 The details of target characteristics used in both plans are presented in Table 3. 
Comparison of dosimetric parameters for lung  
Figs 2A and B show the mean percentage volumes of total lung (A) or functional 
lung (B) receiving ≧5, ≧10, ≧20 and ≧30 Gy (V5, V10, V20, V30, and fV5, 
fV10, fV20, fV30, respectively) for both IMRT and VMAT. Compared with Plan A, 
Plan F reduced V20 in IMRT (mean 1.5 %, p= 0.025), in VMAT (mean 1.6 %, p= 
0.044), V30 in IMRT (mean 1.0 %, p= 0.026), in VMAT (mean 1.3 %, p= 0.048) 
and fV30 in IMRT (mean 1.3 %, p= 0.048). Small reductions were noted in MLD 
(mean 0.23 Gy, p= 0.083 in IMRT, mean 0.5 Gy, p= 0.042 in VMAT) and fMLD 
(mean 0.3 Gy, p= 0.106 in IMRT, mean 0.5 Gy, p= 0.092 in VMAT).  
On the other hand, compared with IMRT, VMAT reduced fV20 in Plan A (mean 
2.0 %, p=0.027), and in Plan F (mean 1.3%, p=0.027), but increased V5 in Plan A 
(mean 16.4 %, p=0.027), in Plan F (mean 15.1%, p=0.005); V10 in Plan A (mean 
8.4 %, p=0.021), in Plan F (mean 7.7 %, p=0.040); fV5 in Plan A (mean 19.0 %, 
p=0.001), in Plan F (mean 18.7 %, p=0.001) and fV10 in Plan A (mean 9.3 %, 
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p=0.025), in Plan F (mean 8.4 %, p=0.045). Significant increases were also seen in 
MLD (mean 1.1 Gy, p= 0.013 in Plan A, mean 0.8 Gy, p= 0.010 in Plan F) and 
fMLD (mean 1.1 Gy, p= 0.037 in Plan A, mean 0.9 Gy, p= 0.002 in Plan F). 
Fig 3 shows V5 and fV5 in IMRT and VMAT of Plan F according to PTV. 
Compared with PTV < 250 cc, IMRT and VMAT significantly increased V5 and 
fV20 in PTV ≥ 250 cc. Additionally, compared with IMRT, VMAT also increased 
V5 and fV5 in PTV ≥ 250 cc significantly (P=0.0096 in V5, p= 0.0032 in fV5). 
Comparison of dosimetric parameters for PTV and organ-at-risk  
Table 4 (A) shows the dosimetric parameters for PTV, organ-at-risk and monitor 
units (MU) between Plans A and F. There were no differences of PTV mean dose, 
HI, CI, mean or maximum dose to organ-at-risk, such as heart, esophagus and 
spinal cord and MU between Plans A and F in both IMRT and VMAT.  
Table 4 (B) shows the dosimetric parameters for PTV, organ-at-risk and MU 
between IMRT and VMAT. Compared with IMRT, VMAT improved HI and CI of 
PTV, especially in Plan F (p=0.040) without change in mean dose to PTV. However, 
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there was no difference in mean or maximum doses to heart and spinal cord 
between IMRT and VMAT, and VMAT increased mean dose to esophagus (mean 
3.9 Gy, p=0.002 in Plan A, mean 3.6 Gy, p=0.003 in Plan F) in both Plans A and F. 
However, IMRT resulted in greater MU than in VMAT in both Plans A and F 
(p=0.008 and 0.003). 
Fig 4 shows dose distribution of case 4. 
  
Discussion 
This study showed that planning of functional image-guided radiotherapy based 
on LAA can improve the dosimetric parameters for lung without a major change of 
PTV coverage and increasing other organ-at-risk doses. IMRT appears to be a good 
treatment planning based on favorable outcomes and in maintaining dosimetric 
predictors of toxicity at acceptable levels for patients who have larger tumors with 
difficult geometry in critical locations (12). However, in as much as reductions in 
MLD, V20 and V10 have been shown by IMRT, it can also increase the volume of 
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lung receiving low doses, such as V5, which may potentially increase lung toxicity 
(13, 14). For delivering safe IMRT for lung cancer, it is important for dosimetric 
factors to be carefully considered. In fact, severe radiation pneumonitis may be 
easily induced by a lower dose in patients with COPD, which is seldom comprised 
of normal lung tissue (7). It is especially in these patients that the functional IMRT 
described here may contribute to minimize the effect of lower doses. 
Several authors have reported on functional imaging modalities for planning of 
radiation treatment. Ventilation imaging is one of the modalities, which is generated 
from CT image volumes of the thorax representing exhale and inhale phases 
obtained from components of the 4D-CT sets using a deformable image registration 
algorithm (8, 15). Yaremko et al reported generation of high functional regions, 
comprised of 90 percentile functional volume, and constituting 10 % of the lung 
volume where the highest ventilation occurred. IMRT plans were generated using 
constraints on the high functional regions. This method led to the result in which the 
mean dose to the high functional region was reduced by 2.9 Gy (8). Yamamoto et al 
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also reported the effectiveness of the ventilation imaging-based functional planning 
(15). In their study, functional lung was divided into high-, moderate- and 
low-functional regions, and the average reductions of the mean dose in the 
high-functional lung were 1.8 Gy for IMRT and 2.0 Gy for VMAT. This was 
achieved by using constraints on each region, for patients who had high-function 
lungs adjacent to the PTV.  
SPECT lung perfusion imaging is the other functional imaging modality, which 
provides information about the function of pulmonary vascular and alveolar 
subunits. Shioyama et al reported that the functional plans reduced the median dose 
of the 50- and 90-percentile hyperperfusion lung to 2.2 and 4.2 Gy, respectively, 
compared with anatomic plans by incorporating perfusion information in IMRT 
planning (9).  
An advantage of these modalities is that several degrees of functional regions can 
be described according to the degree of its regional volume change or perfusion 
distribution. However, the regional physiologic accuracy has not been validated in 
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the ventilation imaging because of the uncertainty regarding the use of deformable 
image registration. Additionally, the use of SPECT lung perfusion imaging is 
limited by the need for separate imaging sessions or fusions in radiotherapy 
planning. 
The functional lung image-derived LAA based on 4D-CT of this study focused 
only on describing non-functional lung regions. The advantages of this method are: 
1) Actual lung function may be easily recognized especially in patients with COPD 
by using LAA-based images. 2) Our LAA approach can be done simply, without the 
need of a sophisticated deformable image registration algorithm. 3) This method may be 
less affected by respiratory motion because of the respiratory-gated technique. 
Consequently, there was limited description of several degrees of functional regions. 
However, CT quantitation using LAA is already an established tool for in vivo 
assessment of COPD, and has been correlated with pulmonary function (10, 11). 
Especially in CT findings of patients with COPD, LAA appears as areas of 
decreased lung attenuation due to an air-trapping phenomenon, which is 
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characterized by progressive air way obstruction and airflow limitation that are not 
reversible with the administration of bronchodilator drugs (16). Therefore 
Zaporozhan et al reported that PE volumes measured from expiratory MDCT scans 
better reflect abnormalities in pulmonary function tests in patients with severe PE 
than in those from inspiratory scans (17). Considering the better reproducibility of 
lung motion, expiratory phases of 4D-CT were selected for this study. A problem 
remains in that 4D-CT data acquisition by this method is affected by respiratory 
motion. Thus, the proper thresholds of CT values for the detection and 
quantification of LAA and the correlations with pulmonary function using this 
method need to be evaluated. Nevertheless, the advantage of this respiratory gated 
method is that it can reduce not only the artifact of respiratory motion but also the 
total lung dose to a minimum.  
Fixed-beam IMRT and VMAT plans were also compared. An advantage of 
VMAT over IMRT is the improvement of target conformity and the potential 
reduction in delivery time, especially in stereotactic body radiotherapy for lung 
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cancer which requires a large number of beams and monitor units (18). On the 
other hand, Schallenkamp et al reported that larger volumes of lungs treated with 
lower doses may be more critical in predicting adverse events than smaller volumes 
treated with higher doses, especially when using the IMRT technique which 
delivers low doses of radiation to large lung volumes (19). Yamamoto et al reported 
that functional IMRT and VMAT planning had a similar impact on each other for 
high-functional lung dose, PTV metrics, and doses to other critical organs (15). In 
our comparison with IMRT, although VMAT reduced fV20 and MU and improved 
HI and CI of PTV, VMAT increased the low dose areas in both plans, especially in 
patients with large PTV. Increasing the low dose area of lung using VMAT in 
patients with large PTV needs to be approached with caution. 
The use of functional lung image-derived LAA into respiratory-gated IMRT or 
VMAT in planning for lung cancer patients may remove the uncertainties of 
quantifying LAA due to respiratory motion, and result in further reductions of total 
and functional lung doses in functional planning. However, several problems need 
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to be addressed for clinical use. Prospective clinical trials will be necessary to 
determine whether treatment results, such as survival and complications, are 
improved by using this functional avoidance treatment planning.  
 
Conclusions 
In conclusion, functional image-guided radiotherapy planning based on LAA in  
respiratory-guided IMRT or VMAT appears to be effective in preserving a  
functional lung in lung cancer patients with COPD. Further investigations are  
needed, including those to clarify several technical problems mentioned above, and  
to conduct prospective clinical trials. 
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Figure legends 
[Fig 1] Fig 1 shows three steps to make the functional lung image-derived low 
attenuation area (LAA) based on four-dimensional computed tomography (4D-CT) 
of case 1.  
[Fig 2] Comparison of V5-30 and fV5-30 in Plan A and F using IMRT and VMAT 
26 
 
(mean ± SD). The p-values shown are only for statistically significant differences  
[Fig 3] Comparison of V5 and fV5 in IMRT and VMAT of Plan F according to 
PTV. The p-values shown are only for statistically significant differences  
[Fig 4] Dose distribution of case 4.  
(A) IMRT plan A, (B) IMRT plan F, (C) VMAT plan A, and (D) VMAT plan F 
show isodose line ≧20 Gy (blue) and functional lung area (green). The isodose 
line ≥20 Gy was decreased at the functional lung in VMAT Plan F (red arrows).  
 
  
           Table 1. Patients' Background 
case age gender histology TNM stage tumor location 
1 81 M non-small T2aN1M0 IIB R.S8 
2 86 M SCC T2aN0M0 IB L.S8 
3 56 M adeno T4N2M0 IIIB R.S1 
4 68 M small T2aN1M0 IIB R.S10 
5 71 M SCC T2aN3M0 IIIB R.S10 
6 74 M small T2aN2M0 IIIA L.S8 
7 68 M SCC T3N2M0 IIIA R.S6 
8 84 M non-small T1N0M0 IA L.S8 
 
         Table 2. Dose constraints for IMRT and VMAT 
       Plan A: anatomical plan     Plan F: functional plan   
    volume (%) Dose (cGy) Priority volume (%) Dose (cGy) Priority 
PTV upper 0 7350 70 0 7350 70 
    10 7200 70 10 7200 70 
  lower 98 7000 80 98 7000 80 
    100 6650 70 100 6650 70 
cord upper 0 4500 90 0 4500 90 
esophagus upper 0 7350 50 0 7350 50 
    35 5500 50 35 5500 50 
heart upper 50 4500 50 50 4500 50 
body upper 0 7500 50 0 7500 50 
lung  upper 10~30 2000 90       
f-lung# upper       10~30 2000 120 
low f-lung (LAA$) upper       10~30 2000 90 
#: functional lung 
       $: low atenuation area 
      
Table 3. Details of Target (PTV), Normal Tissue and Dosimetric Characteristics 
case PTV Total lung Functional lung Defect size Dose constraints 
   (cm3) volume (cm3) volume (cm3) (as % of total lung) of V20 or fV20 
1 158.8 3354.5 1617.6 51.8 <20% 
2 228.3 2819.6 1717.3 39.1 <10% 
3 207.3 3258.1 2302.3 29.3 <10% 
4 278.4 2719.1 2012.5 26 <30% 
5 505.9 2490 2264.1 9.1 <20% 
6 256.4 2885.4 1586.6 45 <25% 
7 561.1 2517.1 1903.4 24.4 <25% 
8 62.4 3124.2 866.8 72.3 <10% 
mean 282.3 2896 1810.4 37.1   
 
 
Table 4. Comparison of dosimetric parameters of PTV and normal tissue 
 between anatomical and functional plans, for IMRT and VMAT (mean ± SD)   
(A)     IMRT     VMAT   
    Anatomical Functional p-value Anatomical Functional p-value 
PTV mean dose (Gy) 72.6 ± 1.2 72.9 ± 0.9 0.155 72.2 ± 1.0 72.3 ± 1.1 0.629 
  Homogeneity index# 1.52 ± 0.08 1.59 ± 0.08 0.056 1.51 ± 0.10 1.51 ± 0.10 1 
  Conformity index$ 2.74 ± 0.72 3.17 ± 1.07 0.128 2.44 ± 0.49 2.53 ± 0.49 0.356 
Heart mean dose (Gy) 19.7 ± 9.7 20.6 ± 10.6 0.214 19.1 ± 10.2 19.9 ± 11.1 0.356 
Esophagus mean dose (Gy) 15.6 ± 11.4 15.6 ± 11.6 0.951 19.5 ± 13.1 19.2 ± 13.2 0.522 
Spinal cord mean dose (Gy) 9.1 ± 6.3 9.2 ± 6.3 0.456 10.3 ± 5.4 9.9 ± 5.8 0.257 
  maximum dose (Gy) 40.6 ± 21.2 40.6 ± 20.5 0.954 42.0 ± 14.6 41.1 ± 15.9 0.269 
MU   786.8± 214.3 817.3± 203.1 0.378 496.5± 60.9 529.9± 56.5 0.149 
        
(B)     Anatomical     Functional   
    IMRT VMAT p-value IMRT VMAT p-value 
PTV mean dose (Gy) 72.6 ± 1.2 72.2 ± 1.0 0.275 72.9 ± 0.9 72.3 ± 1.1 0.129 
  Homogeneity index# 1.52 ± 0.08 1.51 ± 0.10 0.831 1.59 ± 0.08 1.51 ± 0.10 0.077 
  Conformity index$ 2.74 ± 0.72 2.44 ± 0.49 0.23 3.17 ± 1.07 2.53 ± 0.49 0.04 
Heart mean dose (Gy) 19.7 ± 9.7 19.1 ± 10.2 0.639 20.6 ± 10.6 19.9 ± 11.1 0.671 
Esophagus mean dose (Gy) 15.6 ± 11.4 19.5 ± 13.1 0.002 15.6 ± 11.6 19.2 ± 13.2 0.003 
Spinal cord mean dose (Gy) 9.1 ± 6.3 10.3 ± 5.4 0.117 9.2 ± 6.3 9.9 ± 5.8 0.281 
  maximum dose (Gy) 40.6 ± 21.2 42.0 ± 14.6 0.711 40.6 ± 20.5 41.1 ± 15.9 0.888 
MU   786.8± 214.3 496.5± 60.9 0.008 817.3± 203.1 529.9± 56.5 0.003 
#: maximum dose of PTV / minimum dose of PTV 
$: irradiated volume which is covered by minimum dose of PTV / PTV 
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